Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNPR NASDAQ:MSTR NASDAQ:SEZL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$108.52-0.2%$74.77$29.18▼$112.57$728.12M1.46194,265 shs193,675 shsMSTRStrategy$94.03-3.5%$127.80$81.81▼$456.00$34.16B3.5425.18 million shs11.25 million shsSEZLSezzle$180.44-4.3%$138.95$49.50▼$195.71$6.34B6.7625,954 shs1.05 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics-0.16%+3.85%+74.05%+93.03%+164.23%MSTRStrategy-3.53%+0.15%-23.43%-43.53%-79.37%SEZLSezzle-4.30%+1.90%+25.13%+123.57%+24.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$108.52-0.2%$74.77$29.18▼$112.57$728.12M1.46194,265 shs193,675 shsMSTRStrategy$94.03-3.5%$127.80$81.81▼$456.00$34.16B3.5425.18 million shs11.25 million shsSEZLSezzle$180.44-4.3%$138.95$49.50▼$195.71$6.34B6.7625,954 shs1.05 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics-0.16%+3.85%+74.05%+93.03%+164.23%MSTRStrategy-3.53%+0.15%-23.43%-43.53%-79.37%SEZLSezzle-4.30%+1.90%+25.13%+123.57%+24.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNPRMonopar Therapeutics 3.07Buy$108.750.21% UpsideMSTRStrategy 2.88Moderate Buy$266.31183.22% UpsideSEZLSezzle 2.56Moderate Buy$151.33-16.13% DownsideCurrent Analyst Ratings BreakdownLatest MNPR, MSTR, and SEZL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026MNPRMonopar Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/13/2026MNPRMonopar Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/13/2026SEZLSezzle Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$115.00 ➝ $190.007/12/2026SEZLSezzle Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$115.00 ➝ $190.007/7/2026MSTRStrategy BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold ➝ Overweight$130.007/7/2026MSTRStrategy BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2026MSTRStrategy MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$265.00 ➝ $213.007/7/2026SEZLSezzle TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$108.00 ➝ $165.007/6/2026MSTRStrategy Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/30/2026MSTRStrategy Credit Suisse GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$250.006/30/2026MSTRStrategy CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$260.00 ➝ $136.00(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/AMSTRStrategy$477.23M69.05N/AN/A$141.39 per share0.67SEZLSezzle$450.28M13.48$3.65 per share49.43$4.97 per share36.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)MSTRStrategy-$3.85B-$40.16N/A2.41N/A-2,482.01%-26.97%-19.15%7/30/2026 (Estimated)SEZLSezzle$133.13M$4.2142.8628.15N/A30.83%87.46%36.29%8/6/2026 (Estimated)Latest MNPR, MSTR, and SEZL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026MNPRMonopar Therapeutics-$0.67N/AN/AN/AN/AN/A8/6/2026Q2 2026SEZLSezzle$1.03N/AN/AN/A$135.09 millionN/A7/30/2026Q2 2026MSTRStrategy$0.7850N/AN/AN/A$121.88 millionN/A5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/6/2026Q1 2026SEZLSezzle$1.24$1.43+$0.19$1.47$127.74 million$135.54 million5/5/2026Q1 2026MSTRStrategy-$0.8620-$38.25-$37.3880-$38.25$120.75 million$124.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AMSTRStrategyN/AN/AN/AN/AN/ASEZLSezzleN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNPRMonopar TherapeuticsN/A56.0456.04MSTRStrategy0.226.056.05SEZLSezzle0.733.653.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNPRMonopar Therapeutics1.83%MSTRStrategy59.84%SEZLSezzle2.02%Insider OwnershipCompanyInsider OwnershipMNPRMonopar Therapeutics9.70%MSTRStrategy6.49%SEZLSezzle49.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableMSTRStrategy1,539350.45 million327.70 millionOptionableSEZLSezzle54033.63 million16.99 millionNot OptionableMNPR, MSTR, and SEZL HeadlinesRecent News About These CompaniesSezzle Inc. (SEZL) Hits Fresh High: Is There Still Room to Run?July 16 at 10:36 AM | zacks.comSezzle Sees Unusually High Options Volume (NASDAQ:SEZL)July 15 at 12:39 PM | marketbeat.comSezzle (NASDAQ:SEZL) Sets New 1-Year High - Here's WhyJuly 15 at 10:01 AM | marketbeat.comSezzle to Announce Second Quarter 2026 Results and Participate in Upcoming Investor ConferencesJuly 14 at 4:01 PM | globenewswire.comSezzle (NASDAQ:SEZL) Trading Up 8.6% - Should You Buy?July 14 at 1:59 PM | marketbeat.comSezzle (NASDAQ:SEZL) Downgraded by Keefe, Bruyette & Woods to "Hold"July 14 at 7:35 AM | marketbeat.comSezzle stock loses some sizzle after KBW downgrades to market performJuly 13, 2026 | msn.comSezzle (NASDAQ:SEZL) Trading Down 8.3% - What's Next?July 13, 2026 | marketbeat.comKeefe, Bruyette & Woods Reaffirms Market Perform Rating for Sezzle (NASDAQ:SEZL)July 13, 2026 | marketbeat.comSezzle Inc. (NASDAQ:SEZL) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 12, 2026 | marketbeat.comSezzle (NASDAQ:SEZL) CFO Sells $18,500.00 in StockJuly 11, 2026 | americanbankingnews.comThese 7 financial high flyers are still flashing buy signsJuly 11, 2026 | seekingalpha.comCan SEZL's Rally Keep Running Higher? Is it Time to Buy the Stock?July 10, 2026 | zacks.comAccredited Investors Inc. Has $56.12 Million Position in Sezzle Inc. $SEZLJuly 10, 2026 | marketbeat.com3 Reasons Why Growth Investors Shouldn't Overlook Sezzle Inc. (SEZL)July 9, 2026 | zacks.comOppenheimer Says Sezzle (SEZL) Remains Among Fastest Growers in CoverageJuly 9, 2026 | insidermonkey.comSezzle (NASDAQ:SEZL) CFO Lee Dickson Brading Sells 100 Shares of StockJuly 9, 2026 | insidertrades.comLouisiana State Employees Retirement System Takes Position in Sezzle Inc. $SEZLJuly 9, 2026 | marketbeat.comLee Dickson Brading Sells 100 Shares of Sezzle (NASDAQ:SEZL) StockJuly 8, 2026 | marketbeat.comLee Dickson Brading Sells 10,000 Shares of Sezzle (NASDAQ:SEZL) StockJuly 8, 2026 | americanbankingnews.comCvfg LLC Purchases Shares of 43,230 Sezzle Inc. $SEZLJuly 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred SharesBy Jeffrey Neal Johnson | July 5, 2026Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional MoneyBy Jeffrey Neal Johnson | July 16, 2026MNPR, MSTR, and SEZL Company DescriptionsMonopar Therapeutics NASDAQ:MNPR$108.52 -0.17 (-0.16%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$113.38 +4.87 (+4.48%) As of 07/16/2026 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Strategy NASDAQ:MSTR$94.03 -3.44 (-3.53%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$92.82 -1.21 (-1.28%) As of 07/16/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Strategy Incorporated, formerly known as MicroStrategy, provides artificial intelligence-powered enterprise analytics software and services in the United States, Europe, the Middle East, Africa, and internationally. It offers Strategy ONE, a platform that allows non-technical users to access novel and actionable insights for decision-making, and Strategy Cloud for Government, which provides always-on threat monitoring designed to meet the strict technical and regulatory standards of governments and financial institutions. The company also delivers Strategy Support, helping customers achieve system availability and usage goals through responsive troubleshooting; Strategy Consulting, offering architecture and implementation services; and Strategy Education, which includes free and paid learning options. In addition, the company is actively involved in Bitcoin development. The company offers its services through direct sales force and channel partners. It serves the U.S. government, state and local governments, and government agencies, as well as a range of industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.Sezzle NASDAQ:SEZL$180.44 -8.11 (-4.30%) Closing price 07/16/2026 04:00 PM EasternExtended Trading$180.00 -0.44 (-0.24%) As of 07/16/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sezzle Inc. operates as a technology-enabled payments company primarily in the United States and Canada. The company provides payment solution in-store and at online retail stores; and through proprietary payments solution that connects consumers with merchants. It also offers Sezzle Platform that provides a payments solution for consumers that extends credit at the point-of-sale allowing consumers to purchase and receive the ordered merchandise at the time of sale while paying in installments over time; Pay-in-Four, which allows consumers to pay a fourth of the purchase price up front and then another fourth of the purchase price every two weeks thereafter over a total of six weeks; Pay-in-Full that allows consumers to pay for the full value of their order up-front through the Sezzle Platform without the extension of credit; and Pay-in-Two and other alternative installment options, which allow consumer to pay half of the value of their order up-front and the second half in two weeks. In addition, the company provides Sezzle Virtual Card that allows consumers to access the Sezzle Platform in the form of close-end installment loans and shop with merchants that are not integrated with Sezzle; Sezzle Anywhere, a paid subscription service that allows consumers to use their Sezzle Virtual Card at any merchant online or in-store; Sezzle Premium, a paid subscription service that allows its consumers to access large, non-integrated premium merchants; and Sezzle Up, an opt-in feature of the Sezzle Platform. Further, it offers Long-Term Lending through collaboration with third-party lenders and Product Innovation. Sezzle Inc. was incorporated in 2016 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
